AR and prostate cancer: We found a significant reduction in AR activity in C4-2B FR cells after OCM ABI treatment (p = 0.017) suggesting that ABI inhibited the secretion of OB molecules involved in AR-dependent prostate cancer cell proliferation (Figure 2B).